Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FENTANYL CITRATE
Cephalon UK Limited
800 Microgram
Lozenges
2002-01-23
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Actiq 800 micrograms compressed lozenge with integral oromucosal applicator. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One lozenge contains 800 micrograms fentanyl (as citrate). Excipients(s): Each lozenge contains dextrates (equivalent to approximately 2 grams of glucose), sucrose (approximately 30 milligrams confectioner’s sugar) and propylene glycol (part of the artificial berry flavour and imprinting ink) as excipients. _For a full list of excipients, see section 6.1._ 3 PHARMACEUTICAL FORM Compressed lozenge with integral oromucosal applicator. Actiq is formulated as a white to off-white compressed powder drug matrix attached using edible glue to a fracture resistant radio opaque plastic applicator, marked with the dosage strength. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Actiq is indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION In order to minimise the risks of opioid-related side-effects and to identify the “successful” dose, it is imperative that patients be monitored closely by health professionals during the titration process. Any unused Actiq units that the patient no longer requires must be disposed of properly. Patients must be reminded Read the complete document